Emcure Gains as Novo Nordisk’s Wegovy Gets MASH Nod
July 17, 2026July 17, 2026
Emcure Pharmaceuticals shares hit a day high…
Novo Nordisk’s Wegovy gets CDSCO nod for fatty liver disease indication | Company News
The Central Drugs Standard Control Organisation (CDSCO) has approved Danish drugmaker Novo Nordisk’s weight-loss drug Wegovy for…
Novo Nordisk Broadens Arsenal with Implant Deal and MASH Approval as Buyback Sustains Momentum
Novo Nordisk is fighting back against Eli Lilly’s encroachment on multiple fronts — through a novel long-acting implant…
Novo Nordisk’s Wegovy Broadens Its Reach: UK MASH Nod, Medicare Push, and a Billion-Dollar Parent
Novo Nordisk’s bestselling GLP-1 drug is no longer tethered solely to obesity. The Danish pharma giant has locked…
Novo Nordisk Gains UK MASH Approval but Overbought Charts and Cyber Probe Temper Euphoria
Novo Nordisk picked up a new regulatory win in Britain on 3 July 2026, when the MHRA granted…
Novo Nordisk’s MASH Data Strengthens Semaglutide’s Case as Buyback and Earnings Add Context
Novo Nordisk presents Phase 3 ESSENCE subgroup data for semaglutide in MASH, showing efficacy across underrepresented groups. Revenue…
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Novo Nordisk A/S Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients…
Novo Nordisk Targets New Growth as Oral Wegovy Pricing and MASH Data Converge
Novo Nordisk fights compounded competition with $149 oral Wegovy, and presents promising semaglutide data for MASH liver disease,…
Semaglutide MASH Data Broadens Novo Nordisk Case For Undervalued Shares
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Novo Nordisk A/S Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients…
Novo Nordisk’s Pipeline Deepens as Amycretin and MASH Data Bolster a Stretched Stock
Novo Nordisk advances metabolic disease pipeline with Semaglutide success in MASH, high-dose Wegovy weight loss data, and Amycretin…
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Novo Nordisk A/S Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients…